Citigroup cuts target for Baxter International stock from USD 28.00 to USD 27.00

Published on 10/07/2026 at 04:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 2.96 billion, up 5.30 percent year over year. Baxter International stock stood at its EUR 21.54 prior close on October 5, 2026.

Schwarzweiß-Reportage eines Forschers am Mikroskop im klinischen Labor — Becton Dickinson Diagnostik Forscher im Labor dokumentarisch fotografiert, Wertpapier US0718131099 an der Börse, Illustration mit AI erstellt.

Baxter International (ISIN US0718131099) saw Citigroup cut its price target from USD 28.00 to USD 27.00 and keep a Neutral rating on October 5, 2026, according to MarketBeat. The latest second-quarter report put revenue at USD 2.96 billion, creating a clear contrast between operating growth and a more cautious analyst target.

Revenue reaches USD 2.96 billion

MarketBeat reported that Baxter's revenue in the second quarter of 2026 increased 5.30 percent year over year to USD 2.96 billion, compared with a USD 2.80 billion consensus estimate. The same report said earnings per share reached USD 0.56 against a USD 0.37 consensus estimate, a USD 0.19 difference.

The result gives the target cut a more nuanced setting. Revenue exceeded expectations by USD 0.16 billion, while Citigroup's revised target remains USD 5.46 above the Lang & Schwarz prior close in a different currency, so the comparison is directional rather than a valid return calculation.

Analyst targets remain divided

MarketBeat cited two Buy ratings, nine Hold ratings and two Sell ratings, producing a Hold consensus and an average target of USD 22.36. Citigroup's USD 27.00 target is USD 4.64 above that average, even after the bank reduced its own target by USD 1.00.

Investing.com lists October 29, 2026 as Baxter's next earnings date. That report will give investors a fresh test of whether the second-quarter revenue increase can translate into steadier earnings after the target revision.

Connected care adds a strategic angle

Baxter's homepage presents its inaugural Connected Hospital Report, dated September 30, 2026, as a study of hospital technology maturity and workflow integration, according to Baxter. The company describes connected solutions, infusion and nutrition products, pharmaceuticals, surgical technologies and respiratory devices as parts of its portfolio.

Prior close stays at EUR 21.54

Lang & Schwarz shows a prior close of EUR 21.54 for October 5, 2026. Baxter International is listed on the NYSE, where the USD 15.73 to USD 30.00 52-week range and USD 12.6 billion market capitalization were shown for October 6, 2026.

The further course of trading is shown by the continuously updated real-time quote of Baxter International stock.